- Home
- ANEB vs IFRX Comparison
ANEB vs IFRX Comparison
Compare ANEB & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANEB
- IFRX
- Stock Information
- Founded
- ANEB 2020
- IFRX 2007
- Country
- ANEB United States
- IFRX Germany
- Employees
- ANEB N/A
- IFRX N/A
- Industry
- ANEB Biotechnology: Pharmaceutical Preparations
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- ANEB Health Care
- IFRX Health Care
- Exchange
- ANEB Nasdaq
- IFRX Nasdaq
- Market Cap
- ANEB 79.9M
- IFRX 89.5M
- IPO Year
- ANEB 2021
- IFRX 2017
- Fundamental
- Price
- ANEB $1.93
- IFRX $1.53
- Analyst Decision
- ANEB Buy
- IFRX Strong Buy
- Analyst Count
- ANEB 1
- IFRX 2
- Target Price
- ANEB $8.00
- IFRX $13.50
- AVG Volume (30 Days)
- ANEB 13.3K
- IFRX 90.2K
- Earning Date
- ANEB 11-12-2024
- IFRX 10-30-2024
- Dividend Yield
- ANEB N/A
- IFRX N/A
- EPS Growth
- ANEB N/A
- IFRX N/A
- EPS
- ANEB N/A
- IFRX N/A
- Revenue
- ANEB N/A
- IFRX $113,022.00
- Revenue This Year
- ANEB N/A
- IFRX $311.47
- Revenue Next Year
- ANEB N/A
- IFRX $227.11
- P/E Ratio
- ANEB N/A
- IFRX N/A
- Revenue Growth
- ANEB N/A
- IFRX N/A
- 52 Week Low
- ANEB $1.72
- IFRX $1.14
- 52 Week High
- ANEB $3.30
- IFRX $2.10
- Technical
- Relative Strength Index (RSI)
- ANEB 49.10
- IFRX 51.41
- Support Level
- ANEB $1.83
- IFRX $1.43
- Resistance Level
- ANEB $1.96
- IFRX $1.60
- Average True Range (ATR)
- ANEB 0.08
- IFRX 0.08
- MACD
- ANEB 0.00
- IFRX 0.00
- Stochastic Oscillator
- ANEB 49.09
- IFRX 69.77
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.